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Supplemental table 1: DUTY coefficient elements and weightsa 
Index tests Odds Ratio (95% CI) 
Pain/crying when passing urine 
No problem 1 (ref) 
Slight problem 1.73 (0.73-4.06) 
Moderate problem 4.80 (2.30-10.04) 
Severe problem 15.81 (7.37-33.89) 
Smelly urine 
No problem 1 (ref) 
Slight problem 4.28 (2.02-9.05) 
Moderate problem 5.14 (2.60-10.19) 
Severe problem 8.76 (3.76-20.41) 
Previous UTI 
No 1 (ref) 
Yes 2.66 (1.34-5.26) 
Cough  
No problem 1 (ref) 
Slight problem 1.32 (0.68-2.55) 
Moderate problem 1.38 (0.72-2.68) 
Severe problem 0.29 (0.09-0.97) 
Clinician global impression of illness severity (0-10) 
0-1 1 (ref) 
2 1.98 (0.93-4.19) 
3 2.72 (1.28-5.81) 
4-5 3.87 (1.72-8.73) 
6 or more 7.24 (2.59-20.25) 
Abdominal examination: any tenderness  
No 1 (ref) 
Yes 2.24 (0.95-5.25) 
Ear examination: any acute abnormality 
No 1 (ref) 
Yes 0.27 (0.10-0.74) 
  
                                                          
a UTI: urinary tract infection; CI: confidence interval; ref: reference group 
Supplemental table 2: DUTY points elements and weightsb 
Clinical Characteristic (Present / Absent) Points 
Pain/crying passing urine 2 
Smelly urine 2 
Previous UTI 1 
Absence of severe cough 2 
Severe illness present 2 
  
                                                          
b UTI: urinary tract infection. The points-based model was designed to be simple to apply and excluded the two 
variables (abdominal tenderness and absence of ear abnormalities) that contributed least to the  predictive 
accuracy of the statistical model. 
Supplemental table 3: Overview of the DUTY algorithm 
Strategy 
Intermediate 
risk cut-point 
% of children 
above 
intermediate 
cut-point 
Higher risk 
cut-point 
% of children 
above higher 
cut-point 
Coefficient-based algorithmc     
DUTY5% 0.083 4.99 0.142 2.48 
DUTY10% 0.041 10.07 0.083 4.99 
DUTY20% 0.020 20.88 0.041 10.07 
Points-based algorithmd     
DUTY≥6 6 4.60 7 0.71 
DUTY≥5 5 6.96 6 4.60 
DUTY≥4 4 23.04 5 6.96 
DUTY≥3 3 27.76 5 6.96 
  
  
                                                          
c Cut-points represent the probability of urinary tract infection predicted by DUTY coefficient-based algorithm 
d Cut-points represent the score in DUTY points-based algorithm 
Supplemental figure 1: Short-term Markov modele f 
 
 
  
                                                          
e UTI: urinary tract infection; PA: pyelonephritic attack 
f This is a simplification of the actual model which included separate states depending on how quickly the child 
received an antibiotic (delayed vs. immediate) and if the uropathogen was sensitive to the prescribed 
treatment (sensitive vs. resistant) 
Supplemental figure 2a: Medium-term modelg 
 
                                                          
g UTI: urinary tract infection; PA: pyelonephritic attack. Figure represents the movement of patient within the medium 
term model in each year of the model. UTIs are more likely for patients with VUR although part of this increase is mitigated 
for patients with treated VUR. Patients may move between the untreated VUR and treated VUR if they receive a correct 
VUR diagnosis. 
Supplemental figure 2b: Medium-term model, no VUR.h 
 
 
Supplemental figure 2c: Medium-term model, treated VUR. 
 
 
 
Supplemental figure 2d: Medium-term model, untreated VUR. 
 
                                                          
h UTI: urinary tract infection; PA: pyelonephritic attack; VUR: vesicoureteral reflux 
Supplemental figure 3: Long-term modeli 
 
                                                          
i PA: pyelonephritic attack; PRS: progressive renal scarring; ESRD: end-stage renal disease 
Supplemental figure 4: Comparison of observed and modelledj symptom resolution for children a) 
with treated urinary tract infection (n=23) and b) without urinary tract infection (n=291) 
a) 
 
b) 
 
 
  
                                                          
j We used responses to the question ‘How many days since [name of child] joined the DUTY study (day 0) was 
it until [his/her] symptoms improved?’ in the 14 day questionnaire data to calculate symptom duration. A small 
proportion of parents of children both with and without UTI reported symptom recovery times greater than 14 
days hence we extrapolated our estimates to 21 days by which time the vast majority of children were predicted 
to have become asymptomatic. We fitted Weibull models (shape = 1.487, scale = 0.096) for children with UTI 
and (shape = 1.270, scale = 0.1016) for those without. 
0
.2
.4
.6
.8
1
P
ro
p
o
rt
io
n
 w
it
h
 S
y
m
p
to
m
s
0 5 10 15 20
Days Since Consultation
Observed Modelled
0
.2
.4
.6
.8
1
P
ro
p
o
rt
io
n
 w
it
h
 S
y
m
p
to
m
s
0 5 10 15 20
Days Since Consultation
Observed Modelled
Supplemental table 4: Cost and quality of life (utility) parametersk 
Item Estimate (£)l Distribution Source 
Urine sample 7.03 Uniform(3.52,10.55) DUTY 
Urine sample & dipstick 8.10 Uniform(4.05,12.15) DUTY 
Sample attempted but not obtained 1.46 Uniform(0.73,2.19) DUTY 
Laboratory test 6.36 Uniform(3.18,9.54) Carter Report1 
Dipstick test kit 0.39 Uniform(0.2,0.59) DUTY 
GP test interpretation 2.42 Uniform(1.21,3.63) Expert Opinion 
GP call to parents 16.08 Uniform(8.04,24.12) Expert Opinion 
Trimethoprim 2.91 Uniform(1.45,4.36) PCA2 
Amoxicillin 1.29 Uniform(0.64,1.93) PCA2 
Ultrasound 51.88 Uniform(25.94,77.81) NRC3 
MCUG 142.20 Uniform(71.1,213.3) Whiting4 
UTI cost (2 days) 33.73 Uniform(16.86,50.59) DUTY 
UTI daily cost   11.49 Uniform(5.74,17.23) DUTY 
UTI & PA cost (2 days) 50.60 Uniform(15.92,47.76) DUTY & Expert Opinion 
UTI & PA daily cost   17.23 Uniform(8.62,25.85) DUTY & Expert Opinion 
Non UTI cost (2 days) 24.68 Uniform(12.34,37.02) DUTY 
Non UTI daily cost 5.49 Uniform(2.74,8.23) DUTY 
Antibiotic Prophylaxis 24.69 Uniform(12.35,37.04) Nagler5, PCA2 
Dialysis per year 22,467  Uniform(11233.53,33700.59) Baboolal6 
Transplantm 20,186 Uniform(10093,30278) NRC3 
Utilities    
Well Child 1.000 Uniform(0.80,1.00) Assumption 
UTI/ No PA 0.943 Uniform(0.75,1.00) Brisson7 
UTI/ PA 0.711 Uniform(0.57,0.85) Whiting4 
Non UTI Illness 0.943 Uniform(0.75,1.00) Brisson7 
No ESRD (Well Adult) 1.000 Fixed NA 
Dialysis 0.430 Uniform(0.34,0.52) Churchill8 
Transplant 0.840 Uniform(0.67,1.00) Churchill8 
                                                          
k GP: general practitioner; MCUG: micturating cystourethrogram; UTI: urinary tract infection; PA: 
pyelonephritic attack; ESRD: end-stage renal disease 
l All costs were modelled as uniform distributions with lower and upper bounds -/+50% of the mean. All 
utilities were modelled as uniform distributions with lower and upper bounds -/+20% of the mean. 
m Assuming healthcare resource group LA02A. 
Supplemental table 5:  Comparison of mean TAPQOL domain scores by GP Diagnosisn 
Domain 
UTI 
(N=58) 
URTI 
(N=229) 
Viral Illness 
(N=109) 
Otitis Media 
(N=66) 
Chest Infection 
(N=46) 
Tonsillitis 
(N=29) 
Gastroenteritis 
(N=26) 
Other 
(N=112) 
Sleeping 0.598 0.569 0.592 0.538 0.511 0.504 0.603 0.611 
Appetite 0.603 0.654 0.667 0.667 0.607 0.526 0.564 0.683 
Lungs 0.954 0.912 0.939 0.962 0.79 0.848 0.978 0.921 
Stomach 0.803 0.870 0.818 0.889 0.855 0.802 0.638 0.804 
Skin 0.909 0.875 0.896 0.876 0.909 0.888 0.933 0.878 
Motor 0.948 0.939 0.952 0.950 0.924 0.881 0.910 0.942 
Social 0.841 0.799 0.817 0.795 0.819 0.795 0.796 0.795 
Problem 0.741 0.689 0.706 0.697 0.685 0.653 0.676 0.698 
Communication 0.949 0.944 0.971 0.909 0.952 0.847 0.958 0.933 
Anxiety 0.845 0.877 0.867 0.889 0.830 0.902 0.859 0.823 
Positive 0.739 0.750 0.752 0.750 0.685 0.707 0.699 0.733 
Liveliness 0.615 0.702 0.734 0.727 0.645 0.701 0.590 0.687 
 
 
  
                                                          
n UTI: urinary tract infection; URTI: upper respiratory tract infection. Diseases are based on the working diagnosis of the consulting GP except for UTI where only those with laboratory confirmed 
UTI are included 
Supplemental table 6: Sensitivity analysis, short-term costs and outcomeso 
 
UTI Prevalence 
Lab Diagnostic 
Accuracy 
ABX Treatment Effect UTI Utility Simple 
CJ DUTY5% CJ DUTY5% CJ DUTY5% CJ DUTY5% CJ DUTY5% 
Diagnostic pathway          
Urine sample requested (%) 12.64 8.80 9.12 4.79  9.12  4.79  9.12  4.79  9.12  4.79 
Sensitivity – urine sampling 0.564 0.582 0.564 0.582  0.564  0.582  0.564  0.582  0.564  0.582 
Specificity – urine sampling 0.915 0.962 0.915 0.962  0.915  0.962  0.915  0.962  0.915  0.962 
Sensitivity – after laboratory test 0.426 0.439 0.539 0.557  0.426  0.439  0.426  0.439  0.426  0.439 
Specificity – after laboratory test 0.998 0.999 1.000 1.000  0.998  0.999  0.998  0.999  0.998  0.999 
Treatment pathway (children with UTI)           
Immediate, appropriatep antibiotic (%) 36.64 34.05 37.06 34.42 36.64 34.05 36.64 34.05 36.64 34.05 
Laboratory informedq, appropriate antibiotic (%) 12.51 16.55 15.21 20.14 12.51 16.55 12.51 16.55 12.51 16.55 
Inappropriate antibiotic (%) 17.56 16.50 16.65 15.46 17.56 16.50 17.56 16.50 17.56 16.50 
No antibiotic (%) 33.29 32.90 31.09 29.97 33.29 32.90 33.29 32.90 33.29 32.90 
Treatment pathway (children without UTI)           
Antibiotic treatment for UTI (%) 4.79 1.62 4.71 1.57  4.79  1.62  4.79  1.62  4.786  1.616 
Short term costs and outcomes           
Costs per child           
Sampling, culture, antibiotic treatment costs 2.74 2.04 2.00 1.22  1.99  1.22  1.99  1.22  1.99  1.22 
Initial (21 day) health service costs 46.65 45.95 44.05 43.27 43.99 43.21 44.06 43.28 43.94 43.17 
Outcomes           
Asymptomatic days 16.40 16.40 16.35 16.35 16.35 16.35 16.34 16.34 16.34 16.34 
Short term average QALDsr 20.72 20.72 20.73 20.73 20.73 20.73 20.73 20.73 20.73 20.73 
Cost-effectiveness           
iNMBs per child --- 0.70 --- 0.77 --- 0.78 --- 0.78 --- 0.78 
 
 
  
                                                          
o CJ: clinical judgement; UTI: urinary tract infection; QALDs: quality-adjusted life days; iNMB: incremental net monetary benefit 
p (In)appropriate defined as an antibiotic to which the bacterium is (not) sensitive. 
q Antibiotic prescribing determined by laboratory result, usually started a few days after primary care attendance. 
 
s Based on a £20,000 per QALY threshold; compared to clinical judgement; a positive value indicates that the strategy is more cost-effective than clinical judgement 
Supplemental table 7: Sensitivity analysis, medium and long-term costs and outcomest  
 
ESRD Probability PRS Probability 
CJ DUTY5% CJ DUTY5% 
Average number UTI recurrence at 3 years / 10,000 patients 165.5 165.5 165.5 165.5 
% End Stage Renal Disease 0.477 0.477 0.501 0.501 
Average years lived 72.84 72.84 72.83 72.83 
Average Lifetime Cost 303.1 300.7 315.8 313.5 
Average Lifetime QALYs 25.66 25.66 25.65 25.65 
iNMBu, per child --- 2.28 --- 2.28 
 
                                                          
t CJ: clinical judgement; UTI: urinary tract infection; ESRD: end-stage renal disease; QALYs: quality-adjusted life years; iNMB: Incremental net monetary benefit 
u Based on a £20,000 per QALY threshold; compared to clinical judgement strategy; a positive value indicates that the strategy is more cost-effective than clinical judgement 
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